ESMO 2025 – J&J brings a new Rybrevant use into the fold
After promising early data in head and neck, J&J plans a new phase 3, Origami-5.
J&J claims a Tecvayli/Darzalex combo win
The company has seen a PFS and OS benefit in the phase 3 Majestec-3 trial.
M&A analysis: Genmab bucks the bargain basement trend
The group’s $8bn acquisition of Merus was the standout in the third quarter.
Genmab takes its Profound buy into endometrial
The Rainfol-03 trial, in second-line endometrial cancer, builds on recent early data.
The month ahead: August’s upcoming events
Jazz’s Chimerix buy faces its big test.
Columvi avoids its worst-case scenario
Roche’s drug is knocked back in second-line lymphoma, but keeps its third-line nod.
ASCO 2025 – Lilly makes a folate foray against Genmab
LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.
J&J gets a smouldering endorsement
An FDA adcom votes in favour of expansion into a multiple myeloma precursor.
